TABLE OF CONTENTS

TABLE OF CONTENTS

Anderson, 1999, Once-daily controlled-versus immediate-release (cont'd) . . . . . Vol 1 Pg 29
Birns, 2000, A randomized controlled trail comparing (cont'd) . . . . . Vol 1 Pg 33
Boccuzzi, 2002, Utilization patterns associated with tolterodine immediate (cont'd) . Vol 1 Pg 39
Brown, 2000, Urinary incontinence: Does it increase risk for falls and fractures? . . . Vol 1 Pg 40
Chancellor, 2001, A comparison of the effects on salivary output (cont'd) . . . . . Vol 1 Pg 45
Chapple, 2000, Muscarinic receptor antagonists (cont'd) . . . . . Vol 1 Pg 53
Darkow, 2005, Costs associated with the management (cont'd) . . . . . Vol 1 Pg 67
Davis, 1986, Transit of pharmaceutical dosage forms (cont'd) . . . . . Vol 1 Pg 76
Davis, 1988, Relationship between the rate of appearance of oxprenolol (cont'd) . . Vol 1 Pg 83
Dey, 1997, Characteristics of elderly nursing home residents: Data (cont'd) . . . . . Vol 1 Pg 92
Diokno, 2002, Long-term safety of extended-release oxybutynin (cont'd) . . . . . Vol 1 Pg 100
DITROPAN Package Insert 2003 . . . . . Vol 1 Pg 107
DITROPAN XL Package Insert 2004 . . . . . Vol 1 Pg 109
Douchamps, 1988, The pharmacokinetics of oxybutynin in man. . . . . Vol 1 Pg 111
Fick, 2003, Updating the Beers criteria for potentially inappropriate (cont'd) . . . . . Vol 1 Pg 117
Grimby, 1993, The influence of urinary incontinence on the quality (cont'd) . . . . . Vol 1 Pg 126
Gupta, 1999, Quantitative characterization of therapeutic index: Application (cont'd) . . . . . Vol 1 Pg 134
Hu, 2003, Estimated economic costs of overactive bladder (cont'd) . . . . . Vol 1 Pg 147
Hu, 2004, Costs of urinary incontinence and overactive bladder in (cont'd) . . . . . Vol 1 Pg 153
Hughes, 1992, Measurement of oxybutynin and its N-desethyl metabolite (cont'd) . Vol 1 Pg 158
Kachur, 1988, R and S enantiomers of oxybutynin: Pharmacological (cont'd) . . . . . Vol 1 Pg 169
Ko, 2005, The impact of urinary incontinence on quality (cont'd) . . . . . Vol 1 Pg 175
Koch, 1998, Pharmacokinetics and safety of (s)-oxybutynin in normal (cont'd) . . . . . Vol 1 Pg 184
Lown, 1994, Interpatient hetergeneity in expression of (cont'd) . . . . . Vol 1 Pg 187
Lukkari, 1996, Effects of food on the bioavailability of oxybutynin (cont'd) . . . . . Vol 1 Pg 196
Lukkari, 1997, Effect of time interval between food and drug ingestion (cont'd) . . . . Vol 1 Pg 199
Lukkari, 1998, Cytochrome P450 specificity of metabolism and interactions (cont'd) . . . . . Vol 1 Pg 203
Lukkari, 1998, The pharmacokinetics of oxybutynin in unaffected (cont'd) . . . . . Vol 1 Pg 209

Nilsson, 1997, Comparison of a 10 mg controlled release oxybutynin tablet with (cont'd) . . . . . Vol 1 Pg 213
Noronha, 1991, Enantiomers of oxybutynin: in vitro pharmacological (cont'd) . . . . . Vol 1 Pg 223
Paine, 1997, Characterization of interintestinal and intraintestinal (cont'd) . . . . . Vol 1 Pg 229
Sathyan, 2001, Effects of OROS controlled-release delivery (cont'd) . . . . . Vol 1 Pg 240
Sathyan, 2001, Lack of effect on food (cont'd) . . . . . Vol 1 Pg 249
Shaya, 2005, Persistence with overactive bladder (cont'd) . . . . . Vol 1 Pg 255
Sheife, 2005, Central nervous system safety (cont'd) . . . . . Vol 1 Pg 264
Smith, 1998, Comparison of the antimuscarinc and antispasmodic (cont'd) . . . . . Vol 1 Pg 274
Stewart, 2002, Prevalence and burden of overactive bladder in the United States . Vol 1 Pg 281
Thom, 1997, Medically recognized urinary incontinence and (cont'd) . . . . . Vol 1 Pg 291
Varadharajan, 2005, Economic impact of extended-release (cont'd) . . . . . Vol 1 Pg 299
Versi, 2000, Dry mouth with conventional and controlled-release (cont'd) . . . . . Vol 1 Pg 309
Waldeck, 1997, Comparison of oxybutynin and its active metabolite (cont'd) . . . . . Vol 1 Pg 313
Wang, 1995, Muscarinic acetylcholine receptor subtypes mediating urinary (cont'd) . . . . . Vol 1 Pg 318
Zobrist, 2001, Pharmacokinetics of the R- and S-enantiomers (cont'd) . . . . . Vol 1 Pg 326